RxDoctor Payments Data

Ilango Dharmarajan

Adult Health · Santa Fe, NMNPI 1528526464

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 27.9% of the total.

$572in general payments, 2019–2025

Across 18 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$160
  • Insulet Corporation$132
  • Eisai Inc.$79
  • Exact Sciences$57
  • Pfizer$42
  • Lilly USA, LLC$28
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572 in reported general payments places this provider in the 55th percentile of 52 adult health providers in New Mexico.

See all adult health providers in New Mexico

Medicare billing

Part B allowed, 2024
$135,485
Medicare patients
506
Services billed
1,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$109,819
EliquisApixaban106$102,638
JardianceEmpagliflozin42$41,128
TrulicityDulaglutide22$33,861
XareltoRivaroxaban36$32,961
JanuviaSitagliptin Phosphate21$31,162
MyrbetriqMirabegron42$26,089
Janumet XrSitagliptin Phos/Metformin Hcl14$10,466
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,046
Levothyroxine Sodium450$6,027
LinzessLinaclotide11$5,940
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$5,380
Atorvastatin Calcium358$4,292
Tamsulosin Hcl244$4,247
Rosuvastatin Calcium182$3,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$109,81981 claims
PfizerEliquis$42$102,638106 claims
Lilly USA, LLCTrulicity$28$33,86122 claims
AbbVieLinzess, Synthroid$160$7,37453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 52 adult health providers in New Mexico.

Other adult health in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →